‘Please Don’t:’ Analysts Scorn Unilever’s Takeover Ambitions
- “This is a very bad deal,” writes analyst at Bernstein
- Unilever shares plunge 7%, biggest drop in almost two years
A production line inside the Unilever NV factory in Rotterdam, Netherlands.
Photographer: Jasper Juinen/BloombergThis article is for subscribers only.
Want the lowdown on European markets? In your inbox before the open, every day. Sign up here.
Analysts are denouncing Unilever Plc’s 50 billion pound ($68 billion) offer for GlaxoSmithKline Plc’s consumer health business in unusually strong words.